BPC-157 and retatrutide through telehealth: two peptides, two entirely different legal positions

A compounding pharmacy working under section 503A may not use any substance it likes. It may use a substance that has a United States Pharmacopeia monograph, or that is a component of an FDA-approved drug, or that appears on a list the FDA maintains for exactly this purpose, known as the 503A bulks list ^[1].

That list is set by regulation. The current one came from a final rule in February 2019, and the FDA consults an advisory committee, the Pharmacy Compounding Advisory Committee, when it evaluates what to add ^[1]. The committee gives advice; the list changes only through rulemaking.

Hold on to that distinction, because everything below turns on it. A vote is not a rule.

On 16 April 2026 the FDA published a notice in the Federal Register, docket FDA-2025-N-6895, setting a meeting of the advisory committee for 23 and 24 July ^[2]. Four peptide pairs were on the first day's agenda for possible inclusion on the 503A list, BPC-157 among them, in both its free base and acetate forms.

The committee met and voted to recommend adding six of the seven substances it considered: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, recommending against Emideltide ^[3].

Two things about that vote are worth stating plainly.

The first is that FDA staff had recommended against inclusion in their own briefing material, and the committee went the other way ^[3]. That is unusual, and it is the reason the July meeting was watched as closely as it was.

The second is that nothing about your prescription changed that day. The committee advises. The list changes by rulemaking, and the rulemaking has not happened. BPC-157 is still not on the 503A bulks list.

What changed is enforcement. On 28 October 2026 HHS filed a policy saying it will not take action against State-licensed pharmacies and licensed physicians that compound BPC-157 for a named patient while FDA decides whether to list it ^[11]. The conditions are specific: BPC-157 must be the only active ingredient, the route subcutaneous, intramuscular, oral or topical, the bulk substance from an FDA-registered manufacturer named on a certificate of analysis, and serious adverse events reported to FDA. A BPC-157 and TB-500 blend is outside it, and so is anything sold "for research use only". HHS can withdraw the policy. Our report on the policy has all ten conditions.

There is a detail in the Federal Register notice that almost nobody quotes, and it changes how the vote should be read.

For each substance the notice names the use the agency reviewed. For BPC-157, that use is ulcerative colitis ^[2].

Not tendon repair. Not post-workout recovery. Not gut healing in the general sense the marketing uses. The evaluation that produced July's recommendation was about a specific inflammatory bowel condition, which is not what telehealth sites are selling BPC-157 for, and not why most people are looking for it.

If the rulemaking eventually follows the committee, what it permits will be tied to what was evaluated. A recommendation about ulcerative colitis is not a green light for a recovery protocol, and reading it as one is the mistake this section exists to prevent.

The case for BPC-157 is built almost entirely on animal work. Our BPC-157 page goes through that literature; the relevant fact here is how little of it involves humans.

Four studies are registered on ClinicalTrials.gov. One has completed, with 40 participants and no assigned phase. One Phase 2 study is recruiting, with a target of 120. One Phase 1 study has not started recruiting. The fourth is a Phase 1 study from 2016 whose status has sat at unknown ever since.

That is the entire registered human record for a substance being sold by prescription across the country. It is not evidence of harm, and it is not evidence of benefit either. It is an absence, and a seller who describes BPC-157 as clinically proven is describing something that does not exist yet.

Telehealth prices for BPC-157 in 2026 run from roughly $99 to $329 a month depending on the programme, and at least one seller uses a flat one-time visit fee of $39 rather than a subscription.

The spread is wide because the products are not comparable, and the reasons are the same ones our pricing questions exist for: the dose behind the monthly figure is often unpublished, the membership component may or may not be included, and the pharmacy is frequently unnamed. A number without a milligram attached cannot be compared with another number without a milligram attached.

Retatrutide is not in a grey area, and the FDA has written the position down in one place, on its page about unapproved GLP-1 drugs used for weight loss ^[4]. The agency's words, quoted exactly:

"Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition."

There is nothing to interpret there. It is not approved, so there is nothing to prescribe. It is not compoundable, so there is nothing for a pharmacy to make. Our retatrutide page covers where the application stands, and our comparison with tirzepatide covers what the trial numbers do and do not show.

If a telehealth site offers to prescribe you retatrutide, the question is not whether it is a good deal. The question is what exactly is in the vial, because whatever it is, it did not come through the route that answer would require.

We do not name sellers on our own authority. We name the ones the FDA has named, and the letters are public.

Four of them matter here, and read together they show something more useful than a list of bad actors.

That last column is the point. Retatrutide is rarely sold under its own name. It is sold as a code, and the FDA recorded the translation in each letter because the sellers were not going to.

If you are reading a product page and the compound is described as a triple receptor agonist targeting GLP-1, GIP and glucagon, you are reading about retatrutide whatever the label says.

The Mile High letter quotes a document the company distributed through an online community, described as a peptide cheat sheet, giving a starting dose of one to two milligrams weekly and titration up to twelve milligrams weekly ^[6]. That is a human dosing schedule for a drug no regulator has approved for humans, written by the seller.

The Prime Sciences letter quotes the company's own page claiming weight loss of up to 28 percent of body weight, against about 15 percent for semaglutide ^[7].

That 28 percent figure is real. It is the top-dose result from TRIUMPH-1, the Phase 3 trial Eli Lilly reported on 21 May 2026, and we wrote it up ourselves. It was produced by a manufactured, characterised drug given under trial conditions with monitoring. It says nothing whatsoever about the contents of a vial bought online, and using it to sell that vial is the oldest move in this market: borrow the credibility of a trial your product was not in.

On 12 August 2026 Eli Lilly filed six lawsuits in the United States against businesses it accuses of selling black-market retatrutide. The defendants named in the coverage are Aesthetic Envy, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide, and they span compounding pharmacies, medical spas and online sellers ^[9].

The same announcement said Lilly had referred more than 200 people and entities to regulators and law enforcement, and reported that United States customs has been intercepting shipments of illicit GLP-1 products with increasing frequency ^[9].

The shape of that list is the part to notice. This is not only anonymous websites. A medical spa and a pharmacy are businesses with licences, premises and staff, and they are the kind of place a patient would reasonably assume is operating inside the rules.

A preprint posted in August 2026 describes 652 patients who obtained retatrutide direct to consumer rather than through a trial, and compares them with trial participants over a matched window ^[10].

The reported direction is consistent and unflattering: the direct-to-consumer group lost considerably less weight than trial participants, alongside a measurable rise in heart rate. The authors themselves caution that their figure understates the group's real weight loss and that the gap is therefore overstated.

Two cautions of our own. This is a preprint, which means it has not been through peer review, and we are describing its direction rather than quoting figures we have not seen adjudicated. And a study of people who bought an unregulated product cannot separate the drug from the dose from whatever was actually in the vial, which is the whole problem with the market it is studying.

It is still the only human data anyone has on what this market delivers, and its direction is not the one the vendors advertise.

The practical version of everything above fits in a few checks.

Ask what the substance is, by its ordinary name, and what the pharmacy is called on its licence. A seller who answers the second question is a seller operating inside a system that can be checked, and the questions to ask before a first order are built around exactly that.

For BPC-157, understand what you are buying: a substance that is not on the 503A list, compounded under an HHS policy that covers single-ingredient products only and can be withdrawn, whose route onto the list is a recommendation about ulcerative colitis, and whose human record is four registered studies of which one has finished.

For retatrutide, there is no version of the question that ends well. It cannot be compounded, cannot be prescribed, and the only lawful routes are a clinical trial or Lilly's pre-approval expanded access programme, both arranged by a physician rather than a website.

And if a page describes a triple agonist without ever writing the word retatrutide, that omission is the answer.

Editorial note: Informational only, and not medical advice. This page describes the regulatory position of two substances as of 28 October 2026 and does not tell you what is appropriate for you. BPC-157 is not FDA approved and is not on the 503A bulks list, though HHS has said it will not act against compounding it under set conditions; retatrutide is not approved and cannot lawfully be compounded. Companies named here are named because the FDA or a court filing named them first, and each is linked to the document; a warning letter states the agency's findings and a lawsuit is an allegation until decided. Regulatory positions described here can change, and this page carries the date it was written. Decisions about peptide therapy should be made with a licensed healthcare provider familiar with your medical history. See our methodology. Last reviewed September 2026.